The main clinical problems for dental implants are (1) formation of biofilm around the implant—a condition known as peri-implantitis and (2) inadequate bone formation around the implant—lack of osseointegration. Therefore, developing an implant to overcome these problems is of significant interest to the dental community. Chitosan has been reported to have good biocompatibility and anti-bacterial activity. An osseo-inductive recombinant elastin-like biopolymer (P-HAP), that contains a peptide derived from the protein statherin, has been reported to induce biomineralization and osteoblast differentiation. In this study, chitosan/P-HAP bi-layers were built on a titanium surface using a layer-by-layer (LbL) assembly technique. The difference in the water contact angle between consecutive layers, the representative peaks in diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS), X-ray photoelectron spectroscopy (XPS), and the changes in the topography between surfaces with a different number of bi-layers observed using atomic force microscopy (AFM), all indicated the successful establishment of chitosan/P-HAP LbL assembly on the titanium surface. The LbL-modified surfaces showed increased biomineralization, an appropriate mouse pre-osteoblastic cell response, and significant anti-bacterial activity against Streptococcus gordonii, a primary colonizer of tissues in the oral environment
Pet dogs with naturally occurring cancers play an important role in studies of cancer biology and drug development. We assessed tolerability, efficacy, and pharmacokinetic/pharmacodynamic relationships with a first-in-class small molecule inhibitor of valosin-containing protein (VCP/p97), CB-5339, administered to 24 tumor-bearing pet dogs. Tumor types assessed included solid malignancies, lymphomas, and multiple myeloma. Through a stepwise dose and schedule escalation schema, we determined the maximum tolerated dose to be 7.5 mg/kg when administered orally on a 4 days on, 3 days off schedule per week for 3 consecutive weeks. Adverse events were minimal and mainly related to the gastrointestinal system. Pharmacokinetic/pharmacodynamic data suggest a relationship between exposure and modulation of targets related to induction of the unfolded protein response, but not to tolerability of the agent. An efficacy signal was detected in 33% (2/6) of dogs with multiple myeloma, consistent with a mechanism of action relating to induction of proteotoxic stress in a tumor type with abundant protein production. Clinical trials of CB-5339 in humans with acute myelogenous leukemia and multiple myeloma are ongoing.
E14539Background: The AAA (ATPases Associated with diverse cellular Activities) enzyme p97 is an emerging target involved in protein homeostasis. A first-in-class ATP-competitive p97 inhibitor CB-5083 has recently entered phase 1 clinical trials, and non-ATP-competitive p97 inhibitors are being explored. We developed and validated quantitative pharmacodynamic (PD) biomarkers to guide preclinical and early clinical development of p97 inhibitors. Methods: To measure pharmacodynamic response to p97 inhibitors, we focused on three major steps in the mechanism of action: 1) blockage of the ubiquitin proteasome system (UPS); 2) induction of unfolded protein response (UPR) due to endoplasmic reticulum (ER)-associated degradation (ERAD); and 3) execution of apoptosis. Polyubiquitinated proteins linked via lysine-K48 of ubiquitin (K48) provide a specific measure of UPS blockage. A transcription factor CHOP (CCAAT-enhancer-binding homologous protein) in the nuclear fraction provided a measure of UPR, and measuremen...